Myelodysplastic/Myeloproliferative Diseases Treatment (PDQ®)
Cancer Information Summaries « English « Patients « M
Treatment Options for Myelodysplastic/Myeloproliferative Diseases
A link to a list of current clinical trials is included for each treatment section. For some types or stages of cancer, there may not be any trials listed. Check with your doctor for clinical trials that are not listed here but may be right for you.
Chronic Myelomonocytic Leukemia
Treatment of chronic myelomonocytic leukemia (CMML) may include the following:
- Chemotherapy with one or more agents.
- Stem cell transplant.
- A clinical trial of a new treatment.
Check for U.S. clinical trials from NCI’s PDQ Cancer Clinical Trials Registry that are now accepting patients with chronic myelomonocytic leukemia. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. General information about clinical trials is available from the NCI Web site.
Juvenile Myelomonocytic Leukemia
Treatment of juvenile myelomonocytic leukemia (JMML) may include the following:
- Combination chemotherapy.
- Stem cell transplant.
- 13-cis-retinoic acid therapy.
- A clinical trial of a new treatment, such as targeted therapy.
Check for U.S. clinical trials from NCI’s PDQ Cancer Clinical Trials Registry that are now accepting patients with juvenile myelomonocytic leukemia. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. General information about clinical trials is available from the NCI Web site.
Atypical Chronic Myelogenous Leukemia
Treatment of atypical chronic myelogenous leukemia (aCML) may include chemotherapy.
Check for U.S. clinical trials from NCI’s PDQ Cancer Clinical Trials Registry that are now accepting patients with atypical chronic myeloid leukemia. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. General information about clinical trials is available from the NCI Web site.
Myelodysplastic/Myeloproliferative Disease, Unclassifiable
Because myelodysplastic / myeloproliferative disease, unclassifiable (MDS/MPD-UC) is a rare disease, little is known about its treatment. Supportive care treatments are used to manage problems caused by the disease such as infection, bleeding, and anemia.
Check for U.S. clinical trials from NCI’s PDQ Cancer Clinical Trials Registry that are now accepting patients with myelodysplastic/myeloproliferative disease, unclassifiable. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. General information about clinical trials is available from the NCI Web site.
This record was last updated on August 1st, 2008.
About the PDQ Cancer Information Summaries from the National Cancer Institute
PDQ (Physician Data Query) is a comprehensive cancer database published by the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH). It contains peer-reviewed summaries on cancer treatment, screening, prevention, genetics, and supportive care, and complementary and alternative medicine; a registry of cancer clinical trials; and directories of physicians, professionals who provide genetics services, and organizations that provide cancer care.
The PDQ Cancer Information Summaries are peer reviewed and updated monthly by six editorial boards comprised of specialists in adult treatment, pediatric treatment, supportive care, screening and prevention, genetics, and complementary and alternative medicine. The Boards review current literature from more than 70 biomedical journals, evaluate its relevance, and synthesize it into clear summaries. Many of the summaries are also available in Spanish.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PDQ document.